Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T16:25:52.343Z.
Calculation as of: 2026-10-06T16:25:52.343Z.
Quote observation: 2026-10-06T16:18:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8e18e4937bb179ad65bb801f5f057f36d78bd2e4af2c39ec5cecdad017acf428
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$37.76M
PS Ratio
N/A
TTM Avg
65299.11
3Y Avg
21900.20
5Y Avg
13187.22
Market Cap
$33.23M
PS Ratio
1.05
TTM Avg
22.78
3Y Avg
25.26
5Y Avg
324.62
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BriaCell Therapeutics Corp. (BCTX) | $34.97M | N/A | N/A | N/A | N/A |
| Elutia Inc (ELUT)vs › | $35.15M | 2.90 | 2.34 | 2.93 | 2.48 |
| Grace Therapeutics, Inc. (GRCE)vs › | $34.58M | N/A | N/A | N/A | N/A |
| QT Imaging Holdings, Inc. (QTI)vs › | $35.66M | 1.27 | 6.96 | 23.74 | 23.74 |
| Accuray Incorporated (ARAY)vs › | $34.33M | 0.09 | 0.16 | 0.35 | 0.48 |
| DocGo Inc. (DCGO)vs › | $35.92M | 0.12 | 0.22 | 0.47 | 1.32 |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.70M | N/A | N/A | N/A | N/A |
| Edesa Biotech, Inc. (EDSA)vs › | $37.76M | N/A | 65299.11 | 21900.20 | 13187.22 |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.23M | 1.05 | 22.78 | 25.26 | 324.62 |
| EUDA Health Holdings Limited (EUDA)vs › | $32.71M | 2.78 | 7.06 | 18.39 | 15.88 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
Reported statement amounts were converted from USD to USD using the stored FMP exchange-rate calculation.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q4 FY2025Period ended 2025-07-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-16 |
| Q1 FY2026Period ended 2025-10-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-12-11 |
| Q2 FY2026Period ended 2026-01-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-10 |
| Q3 FY2026Period ended 2026-04-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-06-09 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
